Table 4 Case reports and clinical studies with CDK4/6 inhibitors in combination with IR
From: CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
Authors | Patients | Arm | Toxicity | Efficacy |
|---|---|---|---|---|
Hans et al. [83] | Metastatic breast cancer (HR+/HER2-) n = 5 | Palbociclib + Fulvestrant + palliative IR | Digestive toxicity: mucositis (grade 1 = 20%, grade 2 = 20%) Hematological toxicity: grade 3 neutropenia = 40%, grade 3 anemia = 20%, grade 3 thrombopenia = 40% No skin toxicity | Symptom control and pain relief (100%) |
Ippolito et al. [84] | Metastatic breast cancer (HR+) n = 16 | Palbociclib or Ribociclib + palliative IR | Hematological toxicity: neutropenia (grade 2 = 12.5%, grade 3 = 25%, grade 4 = 6.3%) | Absent |
Figura et al. [85] | Brain metastatic breast cancer (HR+) n = 15 lesions = 42 | Palbociclib or Abemaciclib + SBRT | Radionecrosis (2 lesions, 5%) No neurologic toxicity or scalp toxicity | Median OS 36.7 months Six-month local control (88%) Six-month distant brain control (61%) |
Chowd-hary et al. [86] | Metastatic breast cancer (HR+/HER2-) n = 16 | Palbociclib + Fulvestrant or Letrozole + palliative IR | Hematological toxicity: grade 1 = 87.5%, grade 2 = 12.5% No grade 2 or higher cutaneous, neurologic, or gastrointestinal toxicity | Local control and pain relief (100%) |